High prevalence of ESBL-producing Klebsiella pneumoniae in clinical samples from central Cote d'Ivoire by Müller-Schulte, E. et al.
International Journal of Infectious Diseases 91 (2020) 207–209Short Communication
High prevalence of ESBL-producing Klebsiella pneumoniae in
clinical samples from central Côte d’Ivoire
Eloise Müller-Schultea,b,e,**, Marie Nonfra Tuoc,d, Chantal Akoua-Kofﬁc,d,
Frieder Schaumburge, Sören L. Beckerb,f,g,*
aDiagenos, Healthcare Center for Human Genetics, Osnabrück, Germany
bCenter for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg/Saar, Germany
c Laboratoire de Bactériologie-Virologie, Centre Hospitalier Universitaire de Bouaké, Bouaké, Côte d’Ivoire
dUnité de Formation et Recherche Sciences Médicales, Université Alassane Ouattara de Bouaké, Bouaké, Côte d’Ivoire
e Institute of Medical Microbiology, University Hospital Münster, Münster, Germany
f Swiss Tropical and Public Health Institute, Basel, Switzerland
gUniversity of Basel, Basel, Switzerland
A R T I C L E I N F O
Article history:
Received 25 October 2019
Received in revised form 16 November 2019
Accepted 19 November 2019
Keywords:
Africa
Antibiotics
Antimicrobial resistance
Bacteria
Diagnosis
Enterobacterales
Sepsis
A B S T R A C T
Objectives: Infections caused by multidrug-resistant Enterobacterales pose a signiﬁcant challenge to
clinical patient care, particularly in resource-constrained settings where epidemiological data on
antimicrobial resistance are scarce. The aim of this study was to determine the prevalence of extended
spectrum beta-lactamase-(ESBL)-producing Klebsiella pneumoniae among clinical samples from a
teaching hospital in Bouaké, central Côte d’Ivoire.
Methods: Clinical specimens were collected from sterile and non-sterile body sites and were subjected to
microbiological diagnostics (April 2016-June 2017). The antimicrobial susceptibility patterns of K.
pneumoniae were analysed using automated resistance testing and double-disk diffusion to test for ESBL
production. Multiplex PCR was carried out to determine the presence of the resistance-conferring genes
blaCTX-M, blaSHV and blaTEM.
Results: A total of 107 isolates were included, most of which were obtained from bloodstream (39%; n
= 42) and urinary tract infections (39%; n = 42). Among all K. pneumoniae isolates, 84% (n = 90) were ESBL
producers, many of which were also not susceptible to sulfonamides (99%), quinolones (81%) and
aminoglycosides (79%). The majority of ESBL-producing strains harboured all three investigated bla
genes.
Conclusion: The high prevalence of ESBL-producing K. pneumoniae in clinical isolates from Côte d’Ivoire
calls for revised empirical treatment regimens in critically ill patients with suspected Gram-negative
infections, and the establishment of antimicrobial resistance surveillance systems.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The spread of multidrug-resistant bacteria has become a public
health concern on a global scale and particularly affects low- and
middle-income countries (Ndihokubwayo et al., 2013; O’Neill,
2016; Okeke et al., 2005; World Health Organization, 2011).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).sub-Saharan Africa are scarce (Storberg, 2014). A recent systematic
review elucidated that the lack of data on the occurrence of multi-
resistant Gram-negative bacteria (e.g. Klebsiella pneumoniae) is
greatest in West Africa (Workneh et al., 2017). In an attempt to start
ﬁlling this epidemiological gap, we conducted a hospital-based
study on the prevalence of K. pneumoniae with extended spectrum
beta-lactamases (ESBL) among clinical specimens collected at the
University Teaching Hospital Bouaké (UTHB) in Côte d’Ivoire.
Methods
A hospital-based study was conducted between April 2016 and
June 2017 at UTHB in Bouaké, central Côte d’Ivoire, the country’s
only University hospital outside the economic capital Abidjan.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Epidemiological and clinical data of patients with detection of Klebsiella
pneumoniae in clinical specimens at the University Teaching Hospital in Bouaké,
central Côte d’Ivoire, 2016–2017.
Patient characteristics Total (%)
Number of patients 107 (100)
Median age in years (range) 34 (2–84)
Sex
Female 64 (59.8)
Male 43 (40.2)
Ward of admission
Paediatrics 31 (29.0)
Internal medicine 26 (24.3)
Intensive care unit 15 (14.0)
Urology 11 (10.3)
Traumatology 7 (6.5)
Neurology 5 (4.7)
General surgery 3 (2.8)
Neurosurgery 2 (1.9)
Other 7 (6.5)
Biological specimen collected
Blood 42 (39.3)
Urine 42 (39.3)
Swabs (wound or pus) 15 (14.0)
Pleural effusion 3 (2.8)
Bronchial secretion 2 (1.9)
Cerebrospinal ﬂuid 1 (0.9)
Joint aspirate 1 (0.9)
Other 1 (0.9)
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from inpatients and comprised specimens from sterile (e.g. blood
cultures) and non-sterile body sites (e.g. wound swabs). The
decision to send samples for microbiological analysis was based on
the judgement of the attending physician. No speciﬁc exclusion/
inclusion criteria were applied.Table 2
Antimicrobial susceptibility patterns of 107 K. pneumoniae isolates obtained from human
2017. ESBL-producing isolates are stratiﬁed by the distribution of bla genes.
Characteristics
of K.
pneumoniae
isolates
Number
(%)
Presence
of bla
genes
Antimicrobial susceptibility testing (R, resista
Ampicillin/
Sulbactam
Piperacillin/
tazobactam
Cefuroxime Cefot
ESBL
production
90 (84%) R: 90
(100%)
R: 28 (31%) R: 90
(100%)
R: 90
(100%
I: - I: 51 (57%) I: - I: - 
S: - S: 11 (12%) S: - S: - 
1 blaSHV R: 1 I: 1 R: 1 R: 1 
1 blaCTX-M R: 1 I: 1 R: 1 R: 1 
2 blaTEM R: 2 R: 2 R: 2 R: 2 
7 blaSHV
+blaCTX-M
R: 7 R: 2; I: 1; S:
4
R: 7 R: 7 
12 blaCTX-M
+ blaTEM
R: 12 R: 5; I: 5; S:
2
R: 12 R: 12
64 blaSHV +
blaCTX-M
+ blaTEM
R: 64 R: 17; I: 43;
S: 4
R: 64 R: 64
3 Negative
for
blaSHV/
blaCTX-M/
blaTEM
R: 3 R: 2; I: 1 R: 3 R: 3 
No ESBL
production
17 (16%) – R: 4 (24%) R: 1 (6%) R: - R: - 
I: 11 (65%) I: - I: - I: - 
S: 2 (12%) S: 16 (94%) S: 17
(100%)
S: 17
(100%
Total 107
(100%)
R: 94 (88%) R: 28 (27%) R: 90 (84%) R: 90
I: 11 (10%) I: 51 (48%) I: - I: - 
S: 2 (2%) S: 27 (25%) S: 17 (16%) S: 17Clinical samples were processed at the local microbiology
laboratory using routine diagnostic methods (i.e. bacterial culture
on blood agar and MacConkey agar plates). Gram-negative isolates
were provisionally identiﬁed as K. pneumoniae based on colony
morphology and enzymatic tests (API NE, BioMérieux; Marcy
L’Étoile, France). Isolates were subsequently transferred to
Homburg, Germany for conﬁrmatory testing using matrix-assisted
laser desorption/ionization time-of-ﬂight (MALDI-TOF) mass
spectrometry (Maldi Biotyper, Bruker Daltonics; Bremen,
Germany). K. pneumoniae strains were subjected to antibiotic
susceptibility testing (VITEK12, bioMérieux; Marcy L’Étoile,
France). Resistance patterns were interpreted according to break-
points put forth by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST; version 7.1). ESBL-producing K.
pneumoniae were phaenotypically conﬁrmed by double disk
diffusion test containing cefotaxime or ceftazidime with and
without clavulanic acid (Mast Diagnostics; Bootle, United King-
dom). Additionally, genotypic detection of different beta-lacta-
mase encoding genes was carried out in Münster, Germany
(Monstein et al., 2007).
Results
During the study period, we included 107 patients with K.
pneumoniae isolates detected in clinical specimens. There were
more female patients and most samples were obtained from the
paediatric ward (29%), followed by internal medicine (24%) and the
hospital's interdisciplinary intensive care unit (14%). The majority
of isolates stemmed from bloodstream infections (39%) and urine
samples (39%; Table 1).
Automated susceptibility tests and double-disk diffusion
showed a 100% concordance in determining ESBL phenotypes,
and conﬁrmed 90 of the 107 isolates (84%) as ESBL-producing K. infections at the University Teaching Hospital in Bouaké, central Côte d’Ivoire, 2016–
nt; I, intermediate; S, susceptible)
axime Ceftazidime Meropenem Ciproﬂoxacin Gentamicin Sulfamethoxazol/
trimethoprim
)
R: 77 (86%) R: - R: 56 (62%) R: 71 (79%) R: 89 (99%)
I: 12 (13%) I: - I: 17 (19%) I: - I: -
S: 1 (1%) S: 90 (100%) S: 17 (19%) S: 19 (21%) S: 1 (1%)
R: 1 S: 1 R: 1 R: 1 R: 1
R: 1 S: 1 R: 1 R: 1 R: 1
R: 1; S: 1 S: 2 R: 2 R: 1; S: 1 R: 2
R: 7 S: 7 R: 3; I: 1; S: 3 R: 4; S: 3 R: 6; S: 1
 R: 12 S: 12 R: 10; S: 2 R: 9; S: 3 R: 12
 R: 52; I: 12 S: 64 R: 37; I: 16;
S: 11
R: 52; S: 12 R: 64
R: 3 S: 3 R: 2; S: 1 R: 3 R: 3
R: - R: - R: 1 (6%) R: 1 (6%) R: 3 (18%)
I: - I: - I: 1 (6%) I: - I: -
)
S: 17 (100%) S: 17 (100%) S: 15 (88%) S: 16 (94%) S: 14 (82%)
 (84%) R: 77 (72%) R: - R: 57 (53%) R: 72 (67%) R: 92 (86%)
I: 12 (11%) I: - I: 18 (17%) I: - I: -
 (16%) S: 18 (17%) S: 107
(100%)
S: 32 (30%) S: 35 (33%) S: 15 (14%)
E. Müller-Schulte et al. / International Journal of Infectious Diseases 91 (2020) 207–209 209pneumoniae. Multiplex PCR elucidated that 71% of these strains
concomitantly harboured the beta-lactamase-encoding genes
blaSHV, blaCTX-M and blaTEM (Table 2).
Among all detected K. pneumoniae strains, the ESBL prevalence
was 94% in samples stemming from paediatric patients (<18 years)
as opposed to 79% in adults. Phaenotypic resistance to third-
generation cephalosporins (i.e. cefotaxime) was observed in 84% of
all isolates, whereas no resistance to carbapenems was detected.
Non-susceptibility to sulfamethoxazole/trimethoprim (99%), cip-
roﬂoxacin (81%) and gentamicin (79%) was common in ESBL-
producing isolates, whereas these antibiotics remained active
against most K. pneumoniae strains with no ESBL production.
Discussion
We found avery high prevalence of ESBL-producing isolates(84%)
among all K. pneumoniae strains detected in clinical specimens from
a teaching hospital in Côte d’Ivoire, with paediatric patients being
most frequently affected. The ESBL prevalence reported here is
much higher than previously observed for K. pneumoniae in human
samples from south Côte d’Ivoire (Tahou et al., 2017) and from
neighbouring Burkina Faso (Kpoda et al., 2018).
Third-generation cephalosporines are widely used as ﬁrst-line
antibiotics in the empirical treatment of many infections in sub-
Saharan Africa. Indeed, these drugs were the most commonly
administered antibiotics in patients with bloodstream infections at
UTHB, followed by penicillin derivatives, all of which are hydro-
lysed by ESBL (Akoua-Kofﬁ et al., 2015). Given the high prevalence
of ESBL-producing K. pneumoniae detected in our present study,
the empirical use of third-generation cephalosporins in critically ill
patients needs to be urgently revised. Additionally, further studies
are needed to assess the impact of antibiotic self-medication prior
to hospitalisation on the spread of resistance, as antibiotics are
easily accessible ‘over-the-counter’ and without prescription in
parts of Côte d’Ivoire (Hounsa et al., 2010).
Limitations of this study include the relatively small study
population and the lack of additional clinical data (e.g. data on prior
admission to hospital or previous antibiotic treatment) that might
help to identify patients at particular risk of ESBL carriage. Moreover,
furthercharacterisation ofESBL subtypes was not feasibleand we did
not perform environmental sampling, which might have been useful
to detect potential nosocomial transmission patterns.
Our ﬁndings call for an urgent implementation of strategies to
tackle antimicrobial resistance in Côte d’Ivoire. Indeed, the lack of
appropriate microbiological testing facilities (Okeke, 2006) and
the absence of antimicrobial stewardship initiatives (Hamilton and
Bugg, 2018) have been identiﬁed as important factors that are
associated with a suboptimal management of severe infections in
sub-Saharan Africa. Hence, we propose a bundle of measures,
which comprise (i) improved surveillance systems to monitor
emerging resistance patterns (e.g., via antibiotic stewardship
initiatives); (ii) well-equipped microbiology laboratories to obtain
reliable test results; and (iii) improved access to antibiotics with
efﬁcacy against ESBL-producing isolates (e.g. carbapenems) for the
empirical treatment of severely ill patients in Côte d’Ivoire.Conﬂict of interest statement
All authors do not have any conﬂicts of interest to declare.
Funding
This study was partially funded by the Deutsche Forschungs-
gemeinschaft (grant no.: SCHA 1994-5-1). We acknowledge
support by the Deutsche Forschungsgemeinschaft (DFG, German
Research Foundation) and Saarland University within the funding
program Open Access Publishing.
Ethical approval
The study was approved by the medical and scientiﬁc
directorate at UTHB on behalf of the Ministry of Public Health in
Côte d’Ivoire (reference no.: 41-MSHP/CHU-B/DG/DMS/ONAR/16).
Acknowledgements
We gratefully acknowledge technical assistance and support by
Francis Onwugamba and Anna Nimmesgern.
References
Akoua-Kofﬁ C, Tia H, Plo JK, Monemo P, Cissé A, Yao C, et al. Epidemiology of
community-onset bloodstream infections in Bouaké, central Côte d’Ivoire. New
Microbes New Infect 2015;7:100–4.
Hamilton D, Bugg I. Improving antimicrobial stewardship in the outpatient department
of a district general hospital in Sierra Leone. BMJ Open Qual 2018;7:e000495.
Hounsa A, Kouadio L, De Mol P. Self-medication with antibiotics obtained from
private pharmacies in Abidjan, Ivory Coast. Med Mal Infect 2010;40:333–40 [in
French].
Kpoda DS, Ajayi A, Somda M, Traore O, Guessennd N, Ouattara AS, et al. Distribution
of resistance genes encoding ESBLs in Enterobacteriaceae isolated from
biological samples in health centers in Ouagadougou, Burkina Faso. BMC Res
Notes 2018;11:471.
Monstein HJ, Ostholm-Balkhed A, Nilsson MV, Nilsson M, Dornbusch K, Nilsson LE.
Multiplex PCR ampliﬁcation assay for the detection of blaSHV, blaTEM and
blaCTX-M genes in Enterobacteriaceae. APMIS 2007;115:1400–8.
Ndihokubwayo JB, Yahaya AA, Desta AT, Ki-Zerbo G, Odei EA, Keita B, et al.
Antimicrobial resistance in the African region: issues, challenges and actions
proposed. Afr Health Monit 2013;27–30.
Okeke IN. Diagnostic insufﬁciency in Africa. Clin Infect Dis 2006;42:1501–3.
Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, et al. Antimicrobial
resistance in developing countries. Part II: strategies for containment. Lancet
Infect Dis 2005;5:568–80.
O’Neill J. Tackling drug-resistant infections globally: ﬁnal report and recommen-
dations. The review on antimicrobial resistance. 2016 Available online at:
https://amr-review.org/sites/default/ﬁles/160518_Final%20paper_with%20cov-
er.pdf. [Last accessed: 11 October 2019].
Storberg V. ESBL-producing Enterobacteriaceae in Africa – a non-systematic literature
review of research published 2008-2012. Infect Ecol Epidemiol 2014;4:.
Tahou JE, Guessennd NK, Sokouri PD, Gbonon V, Konan F, Kouadio J, et al. Antimicrobial
resistanceof Klebsiella pneumoniae – ESBL producing strains isolated from clinical
specimens in Abidjan (Côte d’Ivoire). Microbiol Res J Int 2017;20:1–7.
World Health Organization (WHO). Step-by-step approach for development and
implementation of hospital antibiotic policy and standard treatment guidelines.
2011 Available online at: http://apps.searo.who.int/PDS_DOCS/B4691.pdf. [Last
accessed: 11 October 2019].
Workneh M, Katz MJ, Lamorde M, Cosgrove SE, Manabe YC. Antimicrobial resistance
of sterile site infections in sub-Saharan Africa: a systematic review. Open Forum
Infect Dis 2017;4: ofx209.
